Immune response to an indigenously developed r-Hepatitis B vaccine in mixed population: Study of an accelerated vaccination schedule

World Journal of Gastroenterology

Volumn 11, Issue 7, 2005, Pages 1037-1039

  Chowdhury, A ^a   Santra, A ^a   Habibullah, C M ^b   Khan, A A ^b   Karunakaramaiah, J ^c   Kishore, T S A ^c   Raju, A V R ^c   Lahiri, S ^c  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b DCMS   (India)

^c Biological E Limited   (India)

Author keywords

Accelerated vaccination schedule; Hepatitis B; Immune response; r hepatitis B vaccines

Indexed keywords

BEVAC; RECOMBINANT HEPATITIS B VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; GROUPS BY AGE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION CONTROL; INJECTION PAIN; INJECTION SITE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POPULATION DISTRIBUTION; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SKIN MANIFESTATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 14844296389     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i7.1037     Document Type: Article

References (15)

1. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999; 12: 351-366
2. Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunization programmes. BMJ 1997; 314: 1033
3. Hong Z, Zou S, Giulivi A. Hepatitis B and its control in Southeast Asia and China. Canada communicable disease report, 2001; 27S3, Available from: htTp://www.hc-sc.gc.ca/pphb-dgspsp/publicat/ccdr-rmtc/ 01vo127/27s3.27s3ke.html
4. Maynard JE, Kane MA, Alter MJ, Hadler SC. Control of Hepatitis B by Immunisation: Global perspectives Viral Hepatitis and Liver Disease. New York: Alan R. Liss, Inc., 1986: 967-969
5. Francis DP. The public's health unprotected. Reversing a decade of underutilization of hepatitis B vaccine. JAMA 1995; 274: 1242-1243
6. Chiaramonte M, Majori S, Ngatchu T, Moschen ME, Baldo V, Benzulli G, Simoncello I, Rocco S, Bertin T, Naccarto R, Trivello R. Two different dosages of yeast derived recombinant hepatitis B vaccines: A comparison of immunogenicity. Vaccine 1996; 14: 135-137
7. Assateerawatt A, Tanphaichitr VS, Suvatte V, Yodthong S. Immunogenicity and efficacy of a recombinant DNA hepatitis B vaccine, Gen Hevac B Pasteur in high risk neonates, school children and healthy adults. Asian Pac J Allergy Immunol 1993; 11: 85-91
8. Just M, Berger R, Just V. Reactogenicity and immunogenicity of a recombinant hepatitis B vaccine compared with a plasma-derived vaccine in young adults. Postgrad Med J 1987; 63 (Suppl 2): 121-123
9. Jilg W, Lorbeer B, Schmidt M, Wilske B, Zoulek G, Deinhartdt F. Clinical evaluation of a recombinant hepatitis B vaccine. Lancet 1984; 2: 1174-1175
10. Hadler SC, de Monzon MA, Lugo DR, Perez M. Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians. Vaccine 1989; 7: 106-110
11. Scheiermann N, Gesemann M, Maurer C, Just M, Berger R. Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules. Vaccine 1990; 8 (Suppl): S44-46
12. Marsano LS, Greenberg RN, Kirkpatrick RB, Zetterman RK, Christiansen A, Smith DJ, De Medina MD, Schiff ER. Comparison of a rapid hepatitis B immunization schedule to the standard schedule for adults. Am J Gastroenterol 1996; 91: 111-115
13. Wahl M, Hermodsson S, Iwarson S. Hepatitis B vaccination with short dose intervals - a possible alternative for post-exposure prophylaxis? Infection 1988; 16: 229-232
14. Saltoglu N, Inal AS, Tasova Y, Kandemir O. Comparison of the accelerated and classic vaccination schedules against Hepatitis B: Three-week Hepatitis B vaccination schedule provides immediate and protective immunity. Ann Clin Microbiol Antimicrob 2003; 2: 10
15. Hollinger FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 1989; 87: 36S-40S